# Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens

Study · id `cardio:ct-nct01365507` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01365507](<https://clinicaltrials.gov/study/NCT01365507>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01365507

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 276 participants.

## Technical summary

Registry record NCT01365507. Randomized; no masking; primary purpose treatment. Start 2011-06 (registry gives no type); primary completion 2012-04 (actual). Results posted on 2015-11-20.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 276 participants (enrolled count; ClinicalTrials.gov record NCT01365507, source copy `cardio:ctgov-nct01365507-2017-03-17`, retrieved 2026-10-26)
- Start date: 2011-06 (registry gives no type) (ClinicalTrials.gov record NCT01365507, source copy `cardio:ctgov-nct01365507-2017-03-17`, retrieved 2026-10-26)
- Primary completion: 2012-04 (actual) (ClinicalTrials.gov record NCT01365507, source copy `cardio:ctgov-nct01365507-2017-03-17`, retrieved 2026-10-26)
- Completion: 2012-04 (actual) (ClinicalTrials.gov record NCT01365507, source copy `cardio:ctgov-nct01365507-2017-03-17`, retrieved 2026-10-26)
- Results first posted: 2015-11-20 (ClinicalTrials.gov record NCT01365507, source copy `cardio:ctgov-nct01365507-2017-03-17`, retrieved 2026-10-26)
- Countries: United States; Malaysia; Mexico; Puerto Rico; South Korea; Thailand; Türkiye (ClinicalTrials.gov record NCT01365507, source copy `cardio:ctgov-nct01365507-2017-03-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01365507-2017-03-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens
- Acronym: BOOST™
- Condition: Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): insulin degludec/insulin aspart
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

## Provenance

Content hash: 14972541cfcece8166de581b381c939739868c5130ad666161f38a2f56a22f55
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
